



11-30-06

Jipw

EXPRESS MAIL NO.: EV 811 559 177 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Lundberg et al.

Confirmation No.: To be assigned

Application No.: 10/583,113
(U.S. National Stage of PCT/SE2004/001879,
filed December 15, 2004)

Group Art Unit: To be assigned

Filed: June 14, 2006

Examiner: To be assigned

For: **DEVICE AND METHOD FOR
ADMINISTERING THERAPEUTIC
AGENTS**

Attorney Docket No.: 11709-006-999
CAM: 791009-999005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A11**, **B01** and **C01-C09** which are listed on the accompanying form entitled "List of References Cited By Applicant." A copy of references **B01** and **C01-C09** are submitted herewith.

References **A01-A11**, which are United States patents or publications, are not being submitted pursuant to 37 C.F.R. § 1.98(a)(2)(ii), unless requested by the Office.

Applicants request that the Examiner review all the references identified on the attached form entitled "List of References Cited By Applicant", and that they be made of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Date November 28, 2006

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203
By: Michael J. Bruner, Reg. No. 47,458

By: Michael J. Bruner (Reg. No. 47,458)

JONES DAY

222 East 41st Street
New York, New York 10017
(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY

12750 High Bluff Drive, Suite 300
San Diego, California 92130
(858) 314-1130

**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)

ATTY. DOCKET NO.

11709-006-999

APPLICATION NO.

10/583,113

APPLICANT

Lundberg et al.

FILING DATE

June 14, 2006

ART UNIT

To be assigned

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	2002/0082221	06/27/02	Herrmann et al.	
	A02	2002/0155174	10/24/02	Benjamin et al.	
	A03	2003/0039697	02/27/03	Zhao et al.	
	A04	2004/0230162	11/18/04	Tan	
	A05	2005/0069595	03/31/05	Chen et al.	
	A06	2005/0192590	09/01/05	Feeley et al.	
	A07	5,007,897	04/16/91	Kalb et al.	
	A08	5,417,657	05/23/95	Hauer	
	A09	5,536,241	07/16/96	Zapol	
	A10	5,858,017	06/12/99	Demopoulos et al.	
	A11	6,824,532	11/30/04	Gillis et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	WO 84/01721	05/10/84	Baxter Travenol Laboratories, Inc.		

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	CARLSSON et al. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide. 2001 Dec;5(6):580-6	
	C02	CARLSSON et al. In vitro evaluation of a new treatment for urinary tract infections caused by nitrate-reducing bacteria. Antimicrob Agents Chemother. 2003 Dec;47(12):3713-8.	
	C03	CARLSSON et al. Intravesical nitric oxide delivery for prevention of catheter-associated urinary tract infections. Antimicrob Agents Chemother. 2005 Jun;49(6):2352-5	
	C04	CARLSSON, S. Antibacterial effects of nitrite in urine. Dissertation submitted April 22, 2005, Department of Surgical Science, Section of Urology and the Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden	
	C05	DUNNE WM Jr. Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev. 2002 Apr;15(2):155-66	
	C06	LUNDBERG et al. Urinary nitrite: more than a marker of infection. Urology. 1997 Aug;50(2):189-91	
	C07	MURTHY et al. Neoplasms in rats and mice fed butylurea and sodium nitrite separately and in combination. Int J	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

11709-006-999

APPLICATION NO.

10/583,113

APPLICANT

Lundberg et al.

FILING DATE

June 14, 2006

ART UNIT

To be assigned

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		Cancer. 1979 Feb;23(2):253-9	
	C08	RUSSELL, C., The effect of nitric oxide on the growth of <i>Escherichia coli</i> . M. Experientia 1965 Nov;21(11):625	
	C09	Stickler DJ, Jones GL, Russell AD. Control of encrustation and blockage of Foley catheters. Lancet. 2003 Apr 26;361(9367):1435-7	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.